Breaking News Instant updates and real-time market news.

EYEN

Eyenovia

$2.63

-0.06 (-2.23%)

, BABA

Alibaba

$156.89

-2.18 (-1.37%)

09:08
01/30/19
01/30
09:08
01/30/19
09:08

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Apple (AAPL), up 5%... Boeing (BA), up 6%... Alibaba (BABA), up 2%... Anthem (ATNM), up 7%... ADP (ADP), up 3%... Ally Financial (ALLY), up 2%. ALSO HIGHER: Eyenovia (EYEN), up 50% after announcing results from Phase 3 MIST-1 study. DOWN AFTER EARNINGS: AT&T (T), down 3%... Invesco (IVZ), down 4%... 8x8. Inc. (EGHT), down 9%... Align Technology (ALGN), down 6%. ALSO LOWER: Juniper (JNPR), down 11% after after guiding FY19 below consensus.

EYEN

Eyenovia

$2.63

-0.06 (-2.23%)

BABA

Alibaba

$156.89

-2.18 (-1.37%)

AAPL

Apple

$154.63

-1.67 (-1.07%)

ANTM

Anthem

$273.02

3.09 (1.14%)

BA

Boeing

$364.95

2.03 (0.56%)

ADP

ADP

$133.98

-1.57 (-1.16%)

ALLY

Ally Financial

$25.31

-0.52 (-2.01%)

T

AT&T

$30.69

0.02 (0.07%)

IVZ

Invesco

$19.05

-0.37 (-1.91%)

EGHT

8x8, Inc.

$19.31

-0.1 (-0.52%)

ALGN

Align Technology

$222.02

0.86 (0.39%)

JNPR

Juniper

$27.94

-0.195 (-0.69%)

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 30

    Jan

  • 05

    Feb

  • 07

    Feb

  • 11

    Feb

  • 13

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 03

    Mar

  • 04

    Mar

  • 14

    Mar

  • 18

    Mar

  • 20

    Mar

  • 28

    May

EYEN Eyenovia
$2.63

-0.06 (-2.23%)

02/20/18
ROTH
02/20/18
INITIATION
Target $20
ROTH
Buy
Eyenovia initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Eyenovia with a Buy rating and a $20 price target, citing a favorable risk/reward profile for the company's emerging pipeline, particularly MicroProst for the treatment of chronic angle closure glaucoma.
10/09/18
HCWC
10/09/18
INITIATION
Target $12
HCWC
Buy
Eyenovia initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Eyenovia with a Buy rating and $12 price target. The company's technology has the potential to change the existing method of administering topical ophthalmic drugs, the analyst tells investors in a research note.
10/09/18
10/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tesla (TSLA) initiated with an Outperform at Macquarie. 2. Tellurian (TELL) initiated with a Buy at BofA/Merrill. 3. NIO Inc. (NIO) initiated with a Neutral at JPMorgan and an Overweight at Morgan Stanley. 4. Eyenovia (EYEN) initiated with a Buy at H.C. Wainwright. 5. Garrett Motion (GTX) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BABA Alibaba
$156.89

-2.18 (-1.37%)

01/14/19
HSBC
01/14/19
NO CHANGE
HSBC
Alibaba price target raised to $190 from $177 at HSBC
HSBC analyst Binnie Wong maintained a Buy rating on Alibaba and raised her target price on shares to $190 from $177. Wong said she expects a promising quarter from Alibaba in her Q3 earnings preview research note, saying she expects "better growth for the core commerce division, implying earnings upside in the near term." The analyst added that she sees an earnings recovery in FY20 and the kick-starting of the monetization of recommendation feeds as key catalysts for the company.
01/22/19
BARD
01/22/19
NO CHANGE
Target $178
BARD
Outperform
Alibaba estimates lowered at Baird as China online sales decelerate
Baird analyst Colin Sebastian lowered his estimates on Alibaba citing the deceleration in China online sales, which he said is consistent with near-term growth headwinds. He reduced his estimates based on the macro softness but said he sees no change to his longer-term view. Sebastian maintained his Outperform rating and $178 price target on Alibaba shares.
01/14/19
BERN
01/14/19
INITIATION
Target $180
BERN
Market Perform
Alibaba assumed with a Market Perform at Bernstein
Bernstein analyst David Dai assumed coverage on Alibaba with a Market Perform and $180 price target.
01/25/19
MKMP
01/25/19
NO CHANGE
Target $245
MKMP
Buy
Alibaba margin pressure to reverse, says MKM Partners
MKM Partners analyst Rob Sanderson kept his Buy rating and $245 price target on Alibaba, saying the stock remains his top pick among mega-caps. The analyst notes that while investors are concerned by the impact of U.S.-China trade tensions on the entire China group, he expects the reversal in Alibaba's margin pressure to serve as a catalyst for the stock to regain normalized valuation. Sanderson further points to postponed monetization of the Recommendations feed as a "substantial" and "untouched" engine for Alibaba's growth.
AAPL Apple
$154.63

-1.67 (-1.07%)

01/30/19
RSBL
01/30/19
NO CHANGE
Target $150
RSBL
Neutral
Apple price target lowered to $150, no near-term catalysts, says Rosenblatt
Rosenblatt analyst Jun Zhang lowered Apple's price target to $150 from $165 and reiterated his Neutral rating. Zhang believes March quarter weakness is reflected in Apple valuation, but thinks there will be further headwinds this year from a slowing smartphone market, the transition to 5G from 4G, and the US-China trade war impacting iPhone sales. The analyst expects 2019 iPhone unit shipments to be down to 175M-180M versus 195M in 2018.
01/30/19
WELS
01/30/19
NO CHANGE
Target $160
WELS
Market Perform
Apple's challenges in China will persist, says Wells Fargo
Wells Fargo analyst Aaron Rakers says shares of Apple are rallying post close on what he views as better-than-feared Q2 guide, and notes that the company expects continued iPhone weakness in Q2 driven by ongoing impacts from FX, slowing upgrades/lack of carrier subsidies, and battery replacement program. While the analyst considers Apple's incremental installed base and services disclosures/expansion to be a positive, he reiterates a Market Perform rating and $160 price target on the shares as he thinks Apple's challenges in China will persist.
01/30/19
BARD
01/30/19
NO CHANGE
Target $185
BARD
Outperform
Apple's 900M iPhone users key to positive thesis, says Baird
Baird analyst William Power said Apple's 900M iPhone users are a powerful Services driver and a key to his positive thesis on the stock. He noted the company's guidance hit his estimate, but missed consensus, adding that its Service gross margins looked strong. Power reiterated his Outperform rating and $185 price target on Apple shares.
01/30/19
OPCO
01/30/19
NO CHANGE
OPCO
Perform
Apple iPhone pricing should stay 'a major hurdle,' says Oppenheimer
Oppenheimer analyst Andrew Uerkwitz says that while Apple cited FX headwind again as one of the major culprits for emerging market weakness, management finally openly admits that iPhone price is another factor. The analyst is not sure such observation will eventually impact design and pricing considerations but believes pricing will stay "a major hurdle" if Apple chooses to protect hardware margin at 30%-plus. Longer term, Uerkwitz sees the least upside from service revenues in Greater China due to robust local Android ecosystem, formidable competition, and handicaps on in-house services from government regulations. The analyst reiterates a Perform rating on the shares.
ANTM Anthem
$273.02

3.09 (1.14%)

01/14/19
SPHN
01/14/19
INITIATION
Target $310
SPHN
Overweight
Anthem initiated with an Overweight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Anthem with an Overweight rating and $310 price target, calling the $4B in gross savings it will realize from insourcing its pharmacy benefits management contract the "most powerful company-specific tailwind" in his coverage group. He also believes the 9% pullback in the stock over the past month has created an attractive entry point, Fidel added.
01/03/19
EVER
01/03/19
UPGRADE
EVER
Outperform
Anthem upgraded to Outperform on elevated growth at Evercore ISI
As previously reported, Evercore ISI upgraded Anthem to Outperform from In Line. Analyst Ross Muken expects Anthem to have elevated growth into 2020 and beyond from the PBM launch, with potential earnings upside outweighing any transaction delays. The analyst also expects increased visibility into services and vertical integration strategies at the March investor day.
01/15/19
PIPR
01/15/19
NO CHANGE
Target $312
PIPR
Overweight
UnitedHealth positioned to outperform in 2019, says Piper Jaffray
Piper Jaffray analyst Sarah James said there "was so much focus" on UnitedHealth's (UNH) earnings call on its medical loss ratio, or MLR, that it pressured the stock early in the day, but she is not concerned. When accounting for adjustments and if one accounts for some Medicaid pressure, UnitedHealth had some improvement in MA or commercial, which could be positive for Humana (HUM) or Anthem (ANTM), according to James. UnitedHealth was also clear in post call conversation that Medicaid headwinds in 2018/19 were largely company specific, which James said leaves her feeling good heading into earnings from Centene (CNC), Molina Healthcare (MOH) and WellCare (WCG). She reiterates her Overweight rating on UnitedHealth, as James sees potential for upside to her earnings estimates and believes the stock is positioned to outperform the group in 2019 as investors move to safer positions.
01/24/19
ARGS
01/24/19
INITIATION
Target $333
ARGS
Buy
Anthem initiated with a Buy at Argus
Argus initiated Anthem with a Buy and $333 price target.
BA Boeing
$364.95

2.03 (0.56%)

01/15/19
JEFF
01/15/19
NO CHANGE
JEFF
Jeffeires finds Aerospace Aftermarket survey positive for Boeing, TransDigm
Jefferies analyst Sheila Kahyaoglu says conclusions from her firm's Aerospace Aftermarket survey indicate a "healthy" outlook for aftermarket volumes of 5%, but one that is slightly below investor expectations of 5%-7%. The lower figures from the survey respondents may be due to a higher proportion of volumes associated with original equipment manufacturers, Kahyaoglu tells investors in a research note. She found the survey results positive for Boeing (BA) and TransDigm (TDG).
01/10/19
01/10/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ship Finance (SFL) initiated with a Neutral at B. Riley FBR. 2. Wipro (WIT) initiated with a Hold at Deutsche Bank. 3. Boeing (BA), Lockheed Martin (LMT), and Raytheon (RTN) were initiated with a Positive at Susquehanna while Northrop Grumman (NOC) and General Dynamics (GD) were initiated with a Neutral. 4. Dollar General (DG) initiated with an Outperform at BMO Capital while Dollar Tree (DLTR) was initiated with a Market Perform. 5. Verint (VRNT) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
01/10/19
NO CHANGE

Morgan Stanley upgrades Boeing, downgrades Lockheed in A&D ratings shake-up
As previously reported, Morgan Stanley analyst Rajeev Lalwani upgraded Boeing (BA) to Overweight from Equal Weight and downgraded Lockheed Martin (LMT) to Equal Weight from Overweight as he adjusted his picks within Aerospace & Defense to focus more on those with visibility to free cash flow growth. Boeing shares are down about 15% from their highs, creating a favorable set-up, and the resilience of the EPS and free cash profile should remain in place within Commercial Aerospace, barring a downturn, Lalwani tells investors. He raised his price target on Boeing shares to $450 from $400. With the F-35 plateauing and pension tailwinds receding, Lalwani sees emerging headwinds on earnings and cash flow post 2020 for Lockheed, he said in explaining his downgrade of the stock. He lowered his price target on Lockheed shares to $300 from $366.
01/10/19
01/10/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Constellation Brands (STZ) upgraded to Buy from Neutral at Goldman Sachs and to Neutral from Sell at Guggenheim. 2. Boeing (BA) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Lockheed Martin (LMT) upgraded to Buy from Hold at Vertical Group. 4. United Continental (UAL) upgraded to Overweight from Neutral at JPMorgan while Alaska Air (ALK) was upgraded to Neutral from Underweight. 5. Twitter (TWTR) double upgraded to Buy from Underperform at BofA/Merrill with analyst Justin Post citing a survey he conducted which showed Twitter penetration increased to 48% of respondents and the percentage of users reporting deceased usage fell slightly. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ADP ADP
$133.98

-1.57 (-1.16%)

11/14/18
LEHM
11/14/18
INITIATION
LEHM
Overweight
Barclays initiates coverage of U.S. payment processors with PayPal as top pick
As noted earlier, Barclays analyst Ramsey El-Assal initiated a group of 20 U.S. companies in the Payments, Processing, and related IT Services sector with Overweight-rated PayPal (PYPL) as his Top Pick. The analyst cites the company's "100% exposure to high-growth digital channels" along with its "clean balance sheet substantial cash position" that bring it a "strategic opportunity. El-Assal is also particularly positive on Overweight-rated WorldPay (WP) based on its strong growth potential from its exposure to "tech-enabled channels" and merger synergies, FirstData (FDC) based on the accelerating growth of its merchant channels, and Square (SQ)," whose Subscription & Services segment is blurring the lines between Payments and software". The analyst contends that the extent of being "tech-enabled" is a key differentiator in the Payments industry, assigning an Overweight rating to Alliance Data Systems (ADS), ADP (ADP), Cardtronics (CATM), Fidelity National (FIS), First Data (FDC), Fiserv (FISV), Fleetcor Technologies (FLT), Global Payments (GPN), Green Dot (GDOT), Mastercard (MA), Total System Services (TSS), Visa (V), and WEX Inc (WEX). El-Assal assigns Equal-weight ratings to EVO Payments (EVOP) and Paychex (PAYX), stating that while the companies are "solid performers" in the space, their valuation is seen as more balanced. The analyst rates MoneyGram (MGI) and Western Union (WU) at Underweight, saying that the former will struggle to re-ignite positive growth as the costs associated with regulatory scrutiny weigh on its profits and the latter will be challenged by "periodic pricing pressure eroding margins over a long period of time."
11/14/18
LEHM
11/14/18
INITIATION
Target $168
LEHM
Overweight
ADP initiated with an Overweight at Barclays
Barclays analyst Ramsey El-Assal initiated ADP with an Overweight and $168 price target.
10/16/18
BOFA
10/16/18
NO CHANGE
BOFA
Ferrari, PayPal added to US 1 List, ADP, NetApp removed at BofA/Merrill
10/31/18
JEFF
10/31/18
NO CHANGE
Target $167
JEFF
Hold
ADP price target raised to $167 from $160 at Jefferies
Jefferies analyst Samad Samana raised his price target on ADP to $167 after its Q1 earnings, margins, and revenue beats. The analyst notes that the company management continues to execute well, as evidenced by its better than anticipated bookings. Samana also keeps his Hold rating on ADP but adds that its estimates are "starting to look conservative".
ALLY Ally Financial
$25.31

-0.52 (-2.01%)

12/20/18
JPMS
12/20/18
UPGRADE
Target $29.5
JPMS
Overweight
Ally Financial upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Shane upgraded Ally Financial to Overweight with a $29.50 price target.
01/23/19
BTIG
01/23/19
NO CHANGE
Target $32
BTIG
Buy
Ally Financial price target lowered to $32 from $39 at BTIG
BTIG analyst Giuliano Bologna lowered his price target for Ally Financial to $32 after taking over coverage from Mark Palmer. The analyst keeps a Buy rating on the shares. Improving origination yields are offsetting cost of capital increases, which should position Ally Financial for multiple expansion as it continues to diversify and improve its earning assets mix, Bologna tells investors in a research note. He views Ally as a "self-help story."
11/02/18
11/02/18
NO CHANGE

Ally Financial providing Carvana with up to $2.3B in financing
Ally Financial (ALLY) is providing up to $2.3B in financing commitments over the next 12 months to support retail contracts from and inventory needs of Carvana (CVNA). In its third year of financing agreements with Carvana, Ally will provide up to $1.25B available for bulk purchases, in addition to providing a $350M warehouse credit facility. The $650M floorplan credit line includes a two-year commitment and represents an increase of $300M over the existing credit line. In the first two years, Ally had agreements to provide up to $2B in financing commitments for retail contracts from Carvana. The latest agreement also includes an increased floorplan credit line and continued vehicle sourcing through Ally's SmartAuction platform.
12/20/18
JPMS
12/20/18
UPGRADE
Target $29.5
JPMS
Overweight
Ally Financial upgraded to Overweight on 'compelling valuation' at JPMorgan
JPMorgan analyst Richard Shane upgraded Ally Financial to Overweight from Neutral with an unchanged price target of $29.50. The analyst sees a "compelling valuation" relative to other consumer finance companies in his coverage universe. Ally is a "compelling outlier in the consumer finance vertical," says the analyst.
T AT&T
$30.69

0.02 (0.07%)

01/02/19
BOFA
01/02/19
NO CHANGE
BOFA
Top 10 US Ideas for Q1 2019 at BofA/Merrill
BofA/Merrill's Alpha Generation Research team introduced its latest Top 10 US Ideas for Q1 2019. The list consists of 9 Buys that are Cigna (CI), Disney (DIS), Equinix (EQIX), Honeywell (HON), Lockheed Martin (LMT), Marvell (MRVL), Procter & Gamble (PG), AT&T (T), and Tapestry (TPR) and 1 Underperform rating which is Campbell Soup (CPB).
01/29/19
01/29/19
DOWNGRADE

Hold
Adtran downgraded to Hold at Needham on margin pressure
As previously reported, Needham analyst Richard Valera downgraded Adtran to Hold from Buy, saying that while the company posted solid Q4 results, the quarter was aided "by the re- emergence of Telmex" and warns that its shift toward international business will results in "structurally lower margins" and limited earnings power. The analyst further notes that he had previously anticipated AT&T (T) and Verizon (VZ) deals as "potentially significant" North America revenue opportunities, but now sees "little confidence either of these programs will ramp substantially over the near to medium term." Valera adds that the recent bounce in Adtran stock has taken its price to within 10% of his prior target, justifying a neutral stance.
01/25/19
HSBC
01/25/19
DOWNGRADE
Target $24
HSBC
Reduce
Dish downgraded to Reduce from Hold at HSBC
HSBC analyst Sunil Rajgopal downgraded Dish (DISH) to Reduce from Hold and cut his price target on the shares to $24 from $38, advocating that investors choose "sturdy carriers" such as Verizon (VZ), T-Mobile (TMUS), AT&T (T) and Comcast (CMCSA). For 2019, Rajgopal expects more fragmentation in the content/pay-TV business as more players enter the OTT content market and he expects the pay TV base to shrink further.
01/23/19
MKMP
01/23/19
NO CHANGE
Target $7.5
MKMP
Buy
Nokia Q4 earnings should be solid, says MKM Partners
MKM Partners analyst Michael Genovese kept his Buy rating and $7.50 price target on Nokia (NOK) ahead of its Q4 results, saying that earnings should be solid with evidence of 5G contribution, even though the outlook on its potential "won't settle the debate". The analyst notes that T-Mobile's (TMUS) 5G network build demand should also yield a good Q1 outlook with added contribution coming from the accelerated 5G plans from KT (KT) and SK Telecom in South Korea. Genovese adds that the 5G debate centers around investment plans by AT&T (T) and Verizon (VZ), but his checks indicate that the former has not made any final decisions on the timing.
IVZ Invesco
$19.05

-0.37 (-1.91%)

01/14/19
FBCO
01/14/19
NO CHANGE
Target $21
FBCO
Neutral
Invesco price target lowered to $21 from $27 at Credit Suisse
Credit Suisse analyst Craig Siegenthaler lowered his price target for Invesco to $21 from $27 ahead of quarterly results. The analyst reiterates a Neutral rating on the shares.
01/11/19
01/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Asset managers BlackRock (BLK), Eaton Vance (EV), Ivesco (IVZ), Affiliated Managers (AMG) and Legg Mason (LM) downgraded to Hold from Buy at Deutsche Bank, with analyst Brian Bedell saying their fundamentals are "unlikely to improve anytime soon." The analyst believes "investor neglect" toward the stocks should continue on fears of a market downturn, as well as due to poor fundamentals from product outflows and pressure on fee rates and operating margins. 2. Starbucks (SBUX) downgraded to Neutral from Buy at Goldman Sachs by analyst Karen Holthouse, saying she remains "reasonably confident" that Starbucks' initiatives to drive digital engagement can lead to a "more stable" 3%-4% comp trajectory in the U.S. over the next few years. However, its valuation has "rapidly re-rated" to reflect this, and gift cards and digital trends could be points of caution in fiscal Q1. The analyst also downgraded Yum! Brands (YUM) to Sell from Neutral. 3. Gap (GPS) downgraded to Underweight from Overweight at Barclays, with analyst Chethan Mallela saying he believes "challenging" traffic trends and "difficult" comparisons cloud visibility into the company's sales growth momentum. Further, the analyst believes the company's cost pressures will be larger than investors anticipate and pose risk to consensus estimates. 4. WW (WTW) downgraded to Neutral from Overweight at JPMorgan by analyst Christina Brathwaite, saying early in the year channel checks point to a weak start to 2019 for the company. The checks suggest traffic to WW''s website and engagement on its mobile app are down double-digit percentages year-over-year, the analyst added. 5. Hanesbrands (HBI) downgraded to Hold from Buy at Deutsche Bank, with analyst Tiffany Kanaga citing a deep dive of the company's international business. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/19
DBAB
01/10/19
DOWNGRADE
DBAB
Deutsche Bank downgrades traditional asset managers
Deutsche Bank analyst Brian Bedell downgraded traditional asset managers, saying their fundamentals are "unlikely to improve anytime soon." The analyst believes "investor neglect" toward the stocks should continue on fears of a market downturn, as well as due to poor fundamentals from product outflows and pressure on fee rates and operating margins. Bedell added that "management teams may more seriously begin to consider M&A should business pressures become more extreme for a prolonged period." The analyst downgraded, to Hold from Buy, BlackRock (BLK), Eaton Vance (EV), Invesco (IVZ), Affiliated Managers Group (AMG), and Legg Mason (LM).
01/10/19
DBAB
01/10/19
DOWNGRADE
Target $18
DBAB
Hold
Invesco downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brian Bedell downgraded Invesco to Hold and lowered his price target for the shares to $18 from $25.
EGHT 8x8, Inc.
$19.31

-0.1 (-0.52%)

10/10/18
WBLR
10/10/18
INITIATION
WBLR
Outperform
8x8, Inc. assumed with an Outperform at William Blair
William Blair analyst Jim Breen assumed coverage of 8x8, Inc. with an Outperform rating.
07/11/18
STFL
07/11/18
INITIATION
Target $25
STFL
Buy
8x8, Inc. initiated with a Buy at Stifel
Stifel analyst Matthew Van Vliet initiated 8x8 with a Buy rating and a price target of $25, saying the company is positioned as a technology leader in cloud communications as a service industry and continues to invest heavily. The analyst adds that its enterprise-grade offerings to businesses of all sizes provide best-in-class communications services in the cloud, noting that the company's management team is now in place to drive increasing enterprise and mid-market penetration.
01/03/19
SPHN
01/03/19
INITIATION
Target $24
SPHN
Overweight
8x8, Inc. initiated with an Overweight at Stephens
Stephens analyst Dmitry Netis started 8x8, Inc. with an Overweight rating and $24 price target. The company is entering the second half of fiscal 2019 with "sustainable momentum" in large customer bookings and an attractive valuation, which creates a favorable risk/reward profile, Netis tells investors in a research note. He says his favorable thesis is supported by a new product cycle helped by the release of the X Series product bundle.
10/30/18
SRCH
10/30/18
INITIATION
SRCH
Hold
8x8, Inc. initiated with a Hold at Summit Insights
Summit Insights initiated 8x8, Inc with a Hold and $20 price target.
ALGN Align Technology
$222.02

0.86 (0.39%)

01/30/19
LEHM
01/30/19
NO CHANGE
Target $260
LEHM
Overweight
Align Technology sales growth should trump earnings reduction, says Barclays
Barclays analyst Steve Valiquette views the key focus of Align Technology's Q4 report as its 2019 outlook, which he says sees higher operational spending to achieve the same 25% sales growth that is already baked into consensus. Investors historically are more willing to accept annual operational spending volatility in med tech companies, as long as there is visibility that it translates into continued organic revenue hyper-growth, Valiquette tells investors in a post-earnings research note titled "Sales Growth Should Still Trump EPS." He believes Align fits this criteria, noting the company's Invisalign franchise is still only 10% penetrated into worldwide orthodontic case starts. As such, the analyst thinks most investors should look past 2019 earnings reduction, "as it makes sense operationally" for Align "to play offense in the 'clear aligner land grab' from traditional metal braces." Valiquette lowered his price target for Align Technology to $260 from $275 and keeps an Overweight rating on the name.
01/30/19
LEER
01/30/19
NO CHANGE
Target $285
LEER
Outperform
Align Technology price target lowered to $285 from $300 at Leerink
Leerink analyst Richard Newitter lowered his price target for Align Technology to $285 from $300 following quarterly results. The analyst reiterates an Outperform rating on the shares as he continues to believe the company can sustain 20%-plus revenue and 18%-plus op profit growth, and as he thinks the stock should see its valuation discount relative to high growth peers narrow given above-average revenue and op profit growth prospects through 2020.
01/30/19
BARD
01/30/19
NO CHANGE
Target $255
BARD
Outperform
Align Technology weakness a buying opportunity, says Baird
Baird analyst Jeff Johnson said the weakness in Align Technology following its Q4 report is a buying opportunity. The analyst said the 2019 margin pressures were a surprise, but he believes they will be short-lived and the volume concerns aren't nearly as big as some might worry. He said the stock could be range-bound, but he sees the company being set up for a good second half. Johnson reiterated his Outperform rating and $255 price target on Align Technology shares.
01/30/19
FBCO
01/30/19
NO CHANGE
Target $270
FBCO
Outperform
Align Technology price target lowered to $270 from $277 at Credit Suisse
Credit Suisse analyst Erin Wilson Wright lowered her price target for Align Technology to $270 from $277 following quarterly results. The analyst reiterates an Outperform rating on the shares saying that while the company's Q4 was admittedly not a clean report and unforeseen expenses will weigh considerably on near-term profitability, she is making no meaningful changes to her volume or ASP assumptions with initial 2019 guidance encouragingly alluding to profit trends back in line with its long-term targets in 2H19.
JNPR Juniper
$27.94

-0.195 (-0.69%)

12/11/18
WOLF
12/11/18
INITIATION
Target $33
WOLF
Outperform
Juniper initiated with an Outperform at Wolfe Research
Wolfe Research analyst analyst Steven Milunovich started Juniper (JNPR) with an Outperform rating and $33 price target, stating that he likes it and Cisco (CSCO) in networking.
01/30/19
01/30/19
DOWNGRADE
Target $25

Underperform
BofA double downgrades Juniper to Underperform on 'weak' fundamentals
As previously reported, BofA Merrill Lynch analyst Tal Liani double downgraded Juniper Networks to Underperform from Buy after the company reported "weak" Q4 results and guidance and management said the demand and pricing trends that are hurting them will likely not improve in the foreseeable future. The company's effort to penetrate cloud vendors with switches will require new products and may take time, Liani added. He lowered his estimates in the wake of the results and guidance and cut his price target on Juniper shares to $25 from $33.
01/30/19
BOFA
01/30/19
DOWNGRADE
BOFA
Underperform
Juniper downgraded to Underperform from Buy at BofA/Merrill
01/30/19
JPMS
01/30/19
NO CHANGE
Target $24
JPMS
Underweight
Juniper price target lowered to $24 from $26 at JPMorgan
JPMorgan analyst Samik Chatterjee lowered his price target for Juniper Networks to $24 from $26 and reiterates an Underweight rating on the shares following the company's Q4 results. The primary driver of the softer revenue outlook was the "familiar cloud driven headwind that has challenged Juniper's top-line growth throughout 2018," Chatterjee tells investors in a research note. He sees these cloud headwinds delaying Juniper's return to revenue growth.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$42.41

0.45 (1.07%)

12:56
02/17/19
02/17
12:56
02/17/19
12:56
Hot Stocks
Pfizer, EMD Serono announce publication of Phase 3 data for BAVENCIO plus INLYTA »

Merck KGaA, which…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 18

    May

MRK

Merck

$79.84

0.9 (1.14%)

, PFE

Pfizer

$42.41

0.45 (1.07%)

12:48
02/17/19
02/17
12:48
02/17/19
12:48
Hot Stocks
Merck presents results from Phase 3 KEYNOTE-426 study »

Merck (MRK) announced…

MRK

Merck

$79.84

0.9 (1.14%)

PFE

Pfizer

$42.41

0.45 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 11

    Apr

  • 18

    May

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

12:42
02/17/19
02/17
12:42
02/17/19
12:42
Hot Stocks
Aveo Pharmaceuticals presents TIVO-3 trial topline results »

Aveo Oncology announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARDM

Aradigm

$0.00

(0.00%)

12:34
02/17/19
02/17
12:34
02/17/19
12:34
Hot Stocks
Aradigm announces plans for reorganization under Chapter 11 »

Aradigm has filed for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.